ChiLdhood Arthritis Risk factor Identification sTudY (CLARITY)
The aetiology of juvenile idiopathic arthritis (JIA) is largely unknown. CLARITY – ChiLdhood Arthritis Risk factor Identification sTudY, is a biobank of biological samples and questionnaire data obtained from cases of JIA and healthy control children in Melbourne, Australia.
The broad aim of the study is to identify genomic and environmental risk factors for the disease.CLARITY is a cross-sectional biobank with retrospective lifecourse data collected at time of enrolment, with the age of participants at enrolment ranging from 0 – 19 years. This data collection includes information on pregnancy and birth and biological samples from newborn (Guthrie) screening cards. Recruitment commenced in 2008 and is ongoing.
| Study Summary | |
|---|---|
| Study name | ChiLdhood Arthritis Risk factor Identification sTudY |
| Study abbreviation | CLARITY |
| Current principal investigator/s |
Jane Munro |
| Primary Institution/s |
Murdoch Children’s Research Institute - MCRI
|
| Major funding source/s |
National Health and Medical Research Council - NHMRC
Arthritis Australia Rebecca L. Cooper Foundation LEW Carty Charitable Foundation ANZ Medical Research and Technologies in Victoria Equity Trustees Lynne Quayle Charitable Trust Fund The Australian Academy of Science The Victorian State Government Operational Infrastructure Support Program Australian Research Council - ARC |
| Study website | https://www.mcri.edu.au/clarity |
| Key reference for study | Ellis, J.A., Ponsonby, A.L., Pezic, A., Chavez, R.A., Allen, R.C., Akikusa, J.D. and Munro, J.E. (2012). CLARITY – ChiLdhood Arthritis Risk factor Identification sTudY. Pediatr Rheumatol Online J. 10(1): 37. doi: 10.1186/1546-0096-10-37. |
| Study focus |
CLARITY is a biobank of children with and without Juvenile Idiopathic Arthritis (JIA) established to identify genomic and environmental disease risk factors for developing JIA. CLARITY also seeks to understand the differences in the natural disease progression in children with JIA, and responses to treatments. Long term, this study will inform the development of new treatments, ideas for prevention, and better care for children living with JIA. |
| Sampling frame |
Cases were recruited from public or private clinics at RCH diagnosed with JIA by a paediatric rheumatologist before 16 years of age. |
| Primary study type | Databank / Biobank |
| Primary participant (at recruitment) | Index child |
| Year commenced |
2008 |
| Is this study ongoing? | Yes - the study is ongoing |
| Ongoing recruitment? | Yes |
| Sample size (N) |
1470 (as of July 2019): 710 cases, 760 controls |
| Survey data available? | Yes |
| Imaging data available? | No |
| Linkage to administrative dataset/s? | No, no consent to link to administrative dataset(s) obtained |
| Biosamples available? | Yes |
| Are data available to others outside study team, with appropriate safeguards and structures in line with the cohort’s ethics and governance processes? | Yes |
| Are there any costs associated with data/sample access for approved requests? | There are usually no costs associated with access |
| Broadest type of participant consent available |
Extended consent (can be used for future ethically approved research related to this project) |
| Study Contacts | |
|---|---|
| Principal investigator/s |
Jane Munro |
| Study Contact |
Phone: (03) 8341 6251 |